Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

12 Health Care Stocks Moving In Wednesday's Intraday Session

Author: Benzinga Insights | December 28, 2022 01:32pm

Gainers

  • Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 314.3% to $16.24 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 35.1 million, which is 16849.9% of its average full-day volume over the last 100 days. The company's market cap stands at $24.6 million.
  • Minerva Surgical (NASDAQ:UTRS) shares moved upwards by 74.83% to $0.28. As of 12:30 EST, Minerva Surgical's stock is trading at a volume of 23.2 million, which is 9788.1% of its average full-day volume over the last 100 days. The company's market cap stands at $8.2 million.
  • Jounce Therapeutics (NASDAQ:JNCE) stock increased by 39.67% to $1.03. The current volume of 30.7 million shares is 4872.3% of Jounce Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $53.2 million.
  • Hoth Therapeutics (NASDAQ:HOTH) stock moved upwards by 35.83% to $4.17. Trading volume for this security as of 12:30 EST is 434.0K, which is 445.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.4 million.
  • Relmada Therapeutics (NASDAQ:RLMD) stock moved upwards by 17.36% to $3.38. Trading volume for Relmada Therapeutics's stock is 192.2K as of 12:30 EST. This is 14.5% of its average full-day volume over the last 100 days. The company's market cap stands at $101.7 million.
  • TransCode Therapeutics (NASDAQ:RNAZ) shares rose 16.99% to $0.47. As of 12:30 EST, this security is trading at a volume of 288.2K shares, making up 9.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.1 million.

Losers

  • Unicycive Therapeutics (NASDAQ:UNCY) stock declined by 32.8% to $0.45 during Wednesday's regular session. Trading volume for Unicycive Therapeutics's stock is 7.7 million as of 12:30 EST. This is 23258.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million.
  • Quotient (NASDAQ:QTNT) stock declined by 32.44% to $0.25. As of 12:30 EST, Quotient's stock is trading at a volume of 1.7 million, which is 237.6% of its average full-day volume over the last 100 days.
  • Minerva Neurosciences (NASDAQ:NERV) stock fell 32.34% to $1.59. Minerva Neurosciences's stock is trading at a volume of 262.5K shares as of 12:30 EST. This is 84.9% of its average full-day volume over the last 100 days. The company's market cap stands at $8.4 million.
  • Virax Biolabs Group (NASDAQ:VRAX) stock fell 16.69% to $0.57. Trading volume for Virax Biolabs Group's stock is 287.3K as of 12:30 EST. This is 23.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.3 million.
  • Exicure (NASDAQ:XCUR) stock fell 15.33% to $1.05. Exicure's stock is trading at a volume of 67.5K shares as of 12:30 EST. This is 31.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.2 million.
  • HTG Molecular Diagnostics (NASDAQ:HTGM) stock fell 15.09% to $3.66. As of 12:30 EST, HTG Molecular Diagnostics's stock is trading at a volume of 1.2 million, which is 128.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: HOTH HTGM JNCE KALA NERV QTNT RLMD RNAZ UNCY UTRS VRAX XCUR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist